TerminatedPhase 3ACTRN12605000231640
A clinical trial of dexmedetomidine or remifentanil sedation for awake fibreoptic intubation
Sponsor
Dr Sarah Harper
Enrollment
20 participants
Start Date
Nov 30, 2004
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- Awake fibreoptic intubation, no contraindication to remifentanil or dexmedetomidine.
Exclusion Criteria1
- Chronic alpha-2 agonist or opioid therapy, allergy or previous adverse reaction to study drugs, uncontrolled hypertension, heart <50, 2nd or 3rd degree heart block, severe ventricular, renal, hepatic or respiratory dysfuction, pregnancy or lactation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dexmedetomidine 0.7 mcg/kg then 0.4 mcg/kg/h until completion of procedure
Dexmedetomidine 0.7 mcg/kg then 0.4 mcg/kg/h until completion of procedure
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000231640
Related Trials
PeRiOperative Medicine Platform Trial
NCT071866342 locations
Monitoring the Depth of Anesthesia and Nociception During the Induction of General Anesthesia in Pediatric Patients
NCT072456541 location
Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia
NCT064976601 location
Comparing the effects of high flow nasal oxygen versus face mask oxygen on expired end tidal oxygen concentration after simulated preoxygenation of obese pregnant people
ACTRN126240002835721 location
The Effect of Volatile Versus Total Intravenous Anaesthesia (TIVA) on the Inducibility of Tachyarrhythmias During Ventricluar Tachycardia (VT) Ablation Procedures
ACTRN126230008256512 locations